DALLAS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023 after the close of the stock market. The Company will host a conference call on Tuesday, November 14, 2023 at 9:00 am Eastern Time to discuss the results.
Investors interested in participating in the live call can dial:
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Contacts:
Investors:
Spectral AI
Vince Capone
General Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.
The Equity Group
Devin Sullivan, Managing Director
This email address is being protected from spambots. You need JavaScript enabled to view it.
Conor Rodriguez, Analyst
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Russo Partners
David Schull
Russo Partners
(858) 717-2310
This email address is being protected from spambots. You need JavaScript enabled to view it.
Guillermo Ruiz, M.D., Ph.D.
Russo Partners
(646) 218-4604
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.71 |
| Daily Change: | 0.03 1.79 |
| Daily Volume: | 399,787 |
| Market Cap: | US$30.030M |
April 24, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
